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Environmental Toxins
and the Brain
For years scientists have sus-
pected that the environment
plays a role in neurodegenera-
tive diseases such as Alzheim-
er's disease, Parkinson's disease,
multiple sclerosis, and dementia.
Only recently have scientists begun to
investigate the complex relationship
between environmental toxins and the
chronic death of neurons, the cells that
serve as information transmitters and
processors in the brain.
Two NIEHS researchers, Jean Harry
and Jau-Shyong Hong, hope their work will
shed light on the mechanisms that trigger
neuroimmune responses-eventually killing
neurons-in the central nervous system.
Ultimately, they hope to uncover drug ther-
apies that could one day slow the progres-
sion ofneurodegenerative diseases.
Scientists theorize that environmental
exposures have a latent effect on the brain,
causing a noticeable degeneration only years
later. "The nervous system is great in com-
pensation," says Harry, a neurotoxicologist.
After a stroke, for example, the victim's sur-
viving neurons sprout and make new con-
nections, striving to keep the brain in bal-
ance. As the system ages, however, it gradu-
ally forfeits the ability to compensate, and
an accelerated aging process may begin.
Jau-Shyong Hong
"You may have been exposed to some-
thing when you were five years old,"
Harry says. "Basically, the whole
process sort of [catches] up with
you.
Rogue Brain Cells
Hong and his colleagues in the neurophar-
macology section of the Laboratory of
Toxicology at the NIEHS have set out to
bolster the theory that microglia-brain
cells that somehow become activated by
neurotoxins or other injuries-kill neurons
in the brain. According to Hong, the
microglia play a critical surveillance role
during the resting stage, just as immune
cells do in the peripheral nervous system.
However, when the brain is injured-
either through adverse environmental expo-
sure, a viral or bacterial infection, trauma,
or stroke-these sentinel cells launch an
out-of-control rampage in the brain.
Suddenly transformed from loyal body-
guards into overactive destroyers, they kill
the very neurons they were intended to pro-
tect. Hong likens the process to misuse or
overuse ofa beneficial drug. Too much ofa
good thing, he says, can be very harmful.
"When [these cells] work too hard, they not
only kill the foreign invader, theyalso kill the
neurons," heexplains.
Hong's experiments studying reactive
gliosis have used an in vitro cell culture sys-
tem. Such a model is necessary,
he contends, to reveal molecular
8 pathways involved in this process.
Hong's experiments have sup-
' ported the theory that overactive
microglia kill neurons, and that,
in contrast, astroglia (large neu-
roglial cells also known as astro-
cytes) produce proteins known to
promote neuronal growth or sur-
vival, which may help to preserve
the neurons under attack by
inflammatory cells. To further
complicate an already complex
relationship, microglia are known
to release mitogens that activate
astroglia, while astroglia produce
growth factors that stimulate
microgliosis.
Hong's work has also focused
on how opioid peptides may
modulate the microglia's func-
tion. His research team has
sought to discover the effects of
endogenous opioid peptides on
the production ofpro-inflamma-
tory cytokines by microglia cells,
as well as their possible relation-
ship to toxin-induced neurode-
generation. "We found opioid
peptides have a very important effect on
microglial function," Hong says. "They
potentially could be used as a therapy for
the neuroimmune system." Hong explains
that opioid peptides tend to dampen the
activity ofthe microglia, helping to prevent
the aberrant activation that destroys neu-
rons. According to Hong, information gen-
erated from this line of research raises the
possibility that inhibition ofeither deleteri-
ous microglial activation or the production
of specific microglial-derived neurotoxins
could provide therapeutic interventions for
neurodegenerative diseases.
Hong's group has also collaborated with
a researcher at Duke University Medical
Center to examine the role of opioid pep-
tides on the interaction between HIV and
microglia. An envelope protein of HIV-
gp120-has been shown to activate the
microglia, which means that, in an AIDS
patient, not only are lymphocytes being
destroyed, but brain cells are being
destroyed as well. "More than 50% of
AIDS patients eventually suffer from AIDS
dementia complex," Hong says.
Triggers ofNeurodegeneration
Harry, who heads the neurotoxicology
group at the NIEHS, suspects that specific
patterns of neurodegeneration may be due
to neuronal-glia signaling interactions.
During the past few years, research on the
nervous system has shown that resident cells
in the central nervous system can produce
cytokines the same way cells in the periph-
eral nervous system do. These cells can react
to injury by initiating a cytokine response,
which has been shown to be associated with
tissue damage. Injury or inflammation
appear to be the precursors ofthis immune-
like response, which could trigger a number
ofneurodegenerative processes in the brain.
Harry's research focuses on understanding
the signaling processes associated with this
inflammatory response and their role in
nervous system damage following exposure
to environmental agents.
According to Harry, an important
mechanism associated with brain injury is
the cytokine inflammatory response.
Inflammation at the site ofinjury, she says,
spurs the microglia to release a number of
factors, creating a cytokine network that
may play a major role in immunologically
mediated neurodegenerative diseases.
Astroglia produce other growth factors and
support the neurons by regulating the neu-
ronal growth and function ofmicroglia.
Harryand hercolleagues have completed
several experiments aimed at identifying the
temporal pattern of pro-inflammatory
cytokine responses during chemically
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induced neurodegeneration. In initial stud-
ies, the researchers examined a prototypic
model of neurodegeneration through sys-
temic administration of the toxic chemical
trimethyltin (TMT) into rats. The TMT
caused neuronal necrosis and neurodegener-
ation in some cells of the hippocampus,
while other cells remained unchanged.
According to Harry, the question ofinterest
is the pattern of degeneration. "Why do
some neurons die while adjacent ones do
not?" sheasks. "Wefoundthatthemicroglia
cells, which have been linked to most ofthe
production ofcytokines, co-localized with
the neurons that were going to degenerate,"
Harryexplains. "And theyco-localized early,
priorto seeinganynecrosis oranyindication
ofneuronal perturbation."
Harry and her colleagues also observed
in those cells an up-regulation-or increased
levels-ofthe cytokines. "So, the microglia
and the cytokines, because oftheir co-local-
ization with neurons, may actually be a dri-
ving force in neurodegeneration," Harry
proposes.
Harry's team also performed experi-
ments using in vitro cultures of glial cells
(astrocytes, microglia, and oligodendro-
cytes) to examine the effects ofTMT on
morphology and cytokine responses in glia
cells alone, without the contribution of
neuronal cells. Their data suggest that
TMT can directly stimulate glial cells with-
out the neuronal signal. Harry hopes that
the in vitro system will allow them to look
more dosely at cellular responses, plus allow
researchers to pharmacologicallymanipulate
various glial factors.
The team is currently evaluating a
mouse model ofTMT that produces a dif-
ferent pattern of hippocampal neuronal
damage. The scientists are finding a con-
centration ofmicroglia around the degener-
ating neurons, again with a concurrent and
most likely related up-regulation of
cytokines. These results prompt the ques-
tion ofwhythemicroglia converge on some
neurons and leave others within the same
region ofthe brain untouched. Harryhopes
to do further research with transgenic ani-
mals and genetic mutants to address this
question and determine whether the
microglia play a neurotoxic role and the
astroglia a protective one. She also wants to
find out if neuronal degeneration is pre-
vented when pro-inflammatory cytokines,
like tumor necrosis factor alpha, are
removed from the equation. In short, Harry
says, "We're trying to find out if the
cytokine response is truly responsible for
the neuronal degeneration, or ifit augments
it, or if it is only an injury response occur-
ringwithin asimilar time period."
The Next Step
Before embarking on the next
level ofin vivo research, the team
plans to study an in vitro culture
system using the same chemical
and identical cells from the hip-
pocampus. "That will help us
identify which intervention
approaches may be successful.
Then we can go back in vivo to
confirm whether we can modu-
late this response," says Harry.
The in vitro approach does
have some disadvantages if used
without caution, according to
Harry. Because the central ner-
vous system is protected by a
blood-brain barrier-the body's
way of keeping unwanted circu-
lating factors at bay-the brain
may be buffered from direct
exposure to certain chemicals.
"There are ways the brain gets Jean Harry
things out, that in culture, it can
never get away from," Harry explains. "And
the other thing is, you never know exactly
what the brain sees," she adds. "Ifyou take
a drug or you're exposed to a chemical, it
can be biometabolized to another form.
[However], the most important limitation
is the inability to mimic the complex nature
ofthe nervous system in an isolated in vitro
system."
For this reason, Harry doesn't advocate
using cultures as an effective screen for
neurotoxicity, arguing that there is no sure
way to have all the systems in place to
accurately determine a chemical's toxicity.
"We don't know the mechanisms oftoxici-
ty to make sure we cover all the possibili-
ties," she concedes. "However, [cultures]
do offer a system to examine specific
mechanistic questions."
Like Hong, Harry also hopes for a drug
to help stem the tide of neurodegeneration
within the brain. "It's probably one that's
already out there; nothing necessarily new,
but one thatwould work on modulating the
immune response," she says. "But we'd first
have to confirm that the drug doesn't cause
problems in the brain." Here again, she
explains, culture systems could pose a prob-
lem: "We're finding things thatare therapeu-
ticagents that,whengiven to theperson, can
have activity in the culture that you don't
necessarilyknowhowto interpret."
Researchers continue to understand
more about neurodegenerative diseases, and
to worksteadily toward therapies that could
one day preserve neurons in the brains of
peoplewho have begun to experience symp-
toms ofneurodegeneration. Preservation is
the key, because the cells in the central ner-
vous system can't regenerate like their
counterparts in the peripheral nervous sys-
tem. The brain comes outfittedwith afinite
number of neurons-billions of them.
Harry says, "you've got one shot at getting
all of them you need. If anything messes
that up, you can work on a lower balance
andyou maybe fine-untilyou age."
JenniferMedlin
Mind-boggling complexiy. By studying the rela-
tionships among different brain cells, scientists
hopeto shed light onthe mechanisms of neurode-
generative diseases.
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